A Review of Hormonal Dynamics and Clinicopathological Features in Women with Breast Cancer
DOI:
https://doi.org/10.61704/pr.523Keywords:
Breast Cancer, Hormonal Dynamics , Estrogen, ProgesteroneAbstract
Breast cancer is a complex, diverse disease that has an effect on people around the world. The rise of breast cancer is associated with hormonal imbalance and emphasizes the importance of understanding complex relationships between hormones and breast tissue. This intensive study intends to detect the importance of hormonal breast cancer imbalance, and analyzes how to affect the growth of large hormones such as estrogen and progesterone. Review checks how hormone imbalance affects the breast tissue. In addition, it discusses the importance of hormone samples for clinical and medical decisions, as well as considering hormonal imbalance as a method to estimate the risk of breast cancer. The study also provides observations of benefits, boundaries and ongoing research projects to adapt to the effectiveness of hormone therapy and remove resistance in the treatment of breast cancer. In this sense, it is important to study the role of hormone dynamics in pathophysiology for breast cancer for the development of our knowledge of the situation and the development of more adapted, effective treatment. Understanding how hormones affect the initiation, spread and resistance of cancer treatment, it is necessary to improve the patient's results and reduce the global stress of breast cancer. The purpose of this review is to provide a comprehensive analysis of how hormonal changes affect breast cancer pathophysiology and the clinical importance of major clinical-pathological features. It tries to improve the results of the treatment by integrating existing data and providing possible paths for the patient's satisfaction with sequence, hormone -focused therapy.
References
Al-Shami, K., Awadi, S., Khamees, A., Alsheikh, A. M., Al-Sharif, S., Bereshy, R. A., et al. (2023). Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon, 9(9), e20224. https://doi.org/10.1016/j.heliyon.2023.e20224
Alkabban, F. M., & Ferguson, T. (2022). Breast Cancer StatPearls. Treasure Island (FL): StatPearls Publishing.
Aly, S. H., Elbadry, A. M., Doghish, A. S., & El-Nashar, H. A. (2024). Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review. Naunyn-schmiedeberg's Archives of Pharmacology, 397(8), 5571-5596. https://doi.org/10.1007/s00210-024-03054-2
Agnoletto, A., & Brisken, C. (2025). Hormone signaling in breast development and cancer. A Guide to Breast Cancer Research: From Cellular Heterogeneity and Molecular Mechanisms to Therapy, 279-307. https://doi.org/10.1007/978-3-031-70875-6_15
Alanko, J., Tanner, M., Vanninen, R., Auvinen, A., & Isola, J. (2021). Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast cancer research and treatment, 187(1), 267-274. https://doi.org/10.1007/s10549-020-06060-z
Brisken, C., & O’Malley, B. (2010). Hormone action in the mammary gland. Cold Spring Harbor perspectives in biology, 2(12), a003178. https://doi.org/10.1101/cshperspect.a003178
Brisken, C., & Scabia, V. (2020). 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. Journal of molecular endocrinology, 65(1), T81-T94. https://doi.org/10.1530/JME-20-0091
Cable, J. K., & Grider, M. H. (2020). Physiology, progesterone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558960/
Criscitiello, C., Fumagalli, D., Saini, K. S., & Loi, S. (2010). Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. OncoTargets and therapy, 1-11. https://doi.org/10.2147/OTT.S10155
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023). A basic review on estrogen receptor signaling pathways in breast cancer. International journal of molecular sciences, 24(7), 6834. https://doi.org/10.3390/ijms24076834
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., ... & Richer, J. K. (2014). Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research, 16(1), R7. https://doi.org/10.1186/bcr3599
Cheng, C. H., Chen, L. R., & Chen, K. H. (2022). Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. International journal of molecular sciences, 23(3), 1376. https://doi.org/10.3390/ijms23031376
Carbone, F. P., Ancona, P., Volinia, S., Terrazzan, A., & Bianchi, N. (2025). Druggable molecular networks in BRCA1/BRCA2-Mutated breast cancer. Biology, 14(3), 253. https://doi.org/10.3390/biology14030253
Chimento, A., De Luca, A., Avena, P., De Amicis, F., Casaburi, I., Sirianni, R., & Pezzi, V. (2022). Estrogen receptors-mediated apoptosis in hormone-dependent cancers. International journal of molecular sciences, 23(3), 1242. https://doi.org/10.3390/ijms23031242
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011). Aromatase, aromatase inhibitors, and breast cancer. The Journal of steroid biochemistry and molecular biology, 125(1-2), 13-22. https://doi.org/10.1016/j.jsbmb.2011.02.001
Di Sante, G., Di Rocco, A., Pupo, C., Casimiro, M. C., & Pestell, R. G. (2017). Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer. Oncotarget, 8(47), 81803. https://doi.org/10.18632/oncotarget.19413
El Sayed, R., El Jamal, L., El Iskandarani, S., Kort, J., Abdel Salam, M., & Assi, H. (2019). Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Frontiers in oncology, 9, 510. https://doi.org/10.3389/fonc.2019.00510
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., ... & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & diseases, 5(2), 77-106. https://doi.org/10.1016/j.gendis.2018.05.001
Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in protein chemistry and structural biology, 116, 135-170. https://doi.org/10.1016/bs.apcsb.2019.01.001
Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy, 11(2), 263-275. https://doi.org/10.1586/era.10.226
He, R., Liu, Y., Fu, W., He, X., Liu, S., Xiao, D., & Tao, Y. (2024). Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression. Molecular cancer, 23(1), 267. https://doi.org/10.1186/s12943-024-02172-y
Howell, S. J., Johnston, S. R., & Howell, A. (2004). The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best practice & research Clinical endocrinology & metabolism, 18(1), 47-66. https://doi.org/10.1016/j.beem.2003.08.002
Hefti, M. M., Hu, R., Knoblauch, N. W., Collins, L. C., Haibe-Kains, B., Tamimi, R. M., & Beck, A. H. (2013). Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Research, 15(4), R68. https://doi.org/10.1186/bcr3462
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M. S., & Catalano, A. (2023). Targeting breast cancer: An overlook on current strategies. International journal of molecular sciences, 24(4), 3643. https://doi.org/10.3390/ijms24043643
Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molecular biology international, 2014(1), 852748. https://doi.org/10.1155/2014/852748
Kittaneh, M., Montero, A. J., & Glück, S. (2013). Molecular profiling for breast cancer: a comprehensive review. Biomarkers in cancer, 5, BIC-S9455. https://doi.org/10.4137/BIC.S9455
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287
Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022). The role of progesterone receptors in breast cancer. Drug design, development and therapy, 305-314. https://doi.org/10.2147/DDDT.S336643
Liu, C., Sun, L., Niu, N., Hou, P., Chen, G., Wang, H., ... & Liu, C. (2025). Molecular classification of hormone receptor-positive/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies. Signal transduction and targeted therapy, 10(1), 97. https://doi.org/10.1038/s41392-025-02181-3
Miziak, P., Baran, M., Błaszczak, E., Przybyszewska-Podstawka, A., Kałafut, J., Smok-Kalwat, J., ... & Stepulak, A. (2023). Estrogen receptor signaling in breast cancer. Cancers, 15(19), 4689. https://doi.org/10.3390/cancers15194689
Manavathi, B., Dey, O., Gajulapalli, V. N. R., Bhatia, R. S., Bugide, S., & Kumar, R. (2013). Derailed estrogen signaling and breast cancer: an authentic couple. Endocrine reviews, 34(1), 1-32. https://doi.org/10.1210/er.2011-1057
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023). Deciphering breast cancer: from biology to the clinic. Cell, 186(8), 1708-1728. https://doi.org/10.1016/j.cell.2023.01.040
Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., et al. (2022). Subtypes of breast cancer. In H. N. Mayrovitz (Ed.), Breast cancer. Exon Publications. https://doi.org/10.36255/exon-publications-breast-cancer-subtypes
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., ... & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell, 187(7), 1617-1635. https://doi.org/10.1016/j.cell.2024.02.041
Rodrigues, I., Fernandes, R., Ferreira, A., Pereira, D., Fernandes, R., Soares, R., & Luís, C. (2025). Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status. Clinical Breast Cancer, 25(4), e331-e340. https://doi.org/10.1016/j.clbc.2024.11.018
Rubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Milillo-Naraine, A. M., Guaqueta, D., & Ergle, A. (2024). Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. International journal of molecular sciences, 25(2), 1064. https://doi.org/10.3390/ijms25021064
Satpathi, S., Gaurkar, S. S., Potdukhe, A., & Wanjari, M. B. (2023). Unveiling the role of hormonal imbalance in breast cancer development: a comprehensive review. Cureus, 15(7), e41737. https://doi.org/10.7759/cureus.41737
Smith-Bindman, R. (2012). Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report. Archives of internal medicine, 172(13), 1023-1027.
Blackadar, C. B. (2016). Historical review of the causes of cancer. World journal of clinical oncology, 7(1), 54. https://doi.org/10.5306/wjco.v7.i1.54
Trabert, B., Bauer, D. C., Buist, D. S., Cauley, J. A., Falk, R. T., Geczik, A. M., ... & Brinton, L. A. (2020). Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA network open, 3(4), e203645.
Takagi, K., Yamaguchi, M., Miyashita, M., Sasano, H., & Suzuki, T. (2022). Diverse role of androgen action in human breast cancer. Endocrine Oncology, 2(1), R102-R111. https://doi.org/10.1530/EO-22-0048
Walsh, E. M., Smith, K. L., & Stearns, V. (2020, August). Management of hormone receptor-positive, HER2-negative early breast cancer. In Seminars in oncology (Vol. 47, No. 4, pp. 187-200). WB Saunders. https://doi.org/10.1053/j.seminoncol.2020.05.010
Wang, X., & Xue, Y. (2023). Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER (-)/PR (+). Frontiers in Endocrinology, 14, 1193592. https://doi.org/10.3389/fendo.2023.1193592
Wang, L., & Di, L. J. (2014). BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?. International journal of biological sciences, 10(5), 566. https://doi.org/10.7150/ijbs.8579
Wu, Z., Xia, F., & Lin, R. (2024). Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021. Journal of hematology & oncology, 17(1), 119. https://doi.org/10.1186/s13045-024-01640-8
Zaha, D. C. (2014). Significance of immunohistochemistry in breast cancer. World journal of clinical oncology, 5(3), 382. https://doi.org/10.5306/wjco.v5.i3.382
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., ... & Wu, C. (2024). Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal transduction and targeted therapy, 9(1), 149. https://doi.org/10.1038/s41392-024-01848-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Rusul A. Alshammary, Marwa M. Al-Attar, Wijdan M. Hameed
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © 2025 by the authors. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may not alter or transform this work in any way without permission from the authors. Non-commercial use, distribution, and copying are permitted, provided that appropriate credit is given to the authors and Al-Hadba University.
